SG11201500233PA - Rspo3 binding agents and uses thereof - Google Patents

Rspo3 binding agents and uses thereof

Info

Publication number
SG11201500233PA
SG11201500233PA SG11201500233PA SG11201500233PA SG11201500233PA SG 11201500233P A SG11201500233P A SG 11201500233PA SG 11201500233P A SG11201500233P A SG 11201500233PA SG 11201500233P A SG11201500233P A SG 11201500233PA SG 11201500233P A SG11201500233P A SG 11201500233PA
Authority
SG
Singapore
Prior art keywords
binding agents
rspo3 binding
rspo3
agents
binding
Prior art date
Application number
SG11201500233PA
Other languages
English (en)
Inventor
Austin L Gurney
Christopher J Bond
Original Assignee
Oncomed Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharm Inc filed Critical Oncomed Pharm Inc
Publication of SG11201500233PA publication Critical patent/SG11201500233PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11201500233PA 2012-07-13 2013-07-12 Rspo3 binding agents and uses thereof SG11201500233PA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261671421P 2012-07-13 2012-07-13
US201361753184P 2013-01-16 2013-01-16
US201361789156P 2013-03-15 2013-03-15
US201361826747P 2013-05-23 2013-05-23
PCT/US2013/050300 WO2014012007A2 (fr) 2012-07-13 2013-07-12 Agents de liaison des protéines rspo3 et leurs utilisations

Publications (1)

Publication Number Publication Date
SG11201500233PA true SG11201500233PA (en) 2015-04-29

Family

ID=49914164

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201500233PA SG11201500233PA (en) 2012-07-13 2013-07-12 Rspo3 binding agents and uses thereof

Country Status (24)

Country Link
US (3) US9181333B2 (fr)
EP (1) EP2872175A4 (fr)
JP (1) JP6335896B2 (fr)
KR (1) KR20150036603A (fr)
CN (1) CN104854132A (fr)
AU (1) AU2013289990B2 (fr)
BR (1) BR112015000776A2 (fr)
CA (1) CA2878868A1 (fr)
CL (1) CL2015000097A1 (fr)
EA (1) EA032038B1 (fr)
EC (1) ECSP15005280A (fr)
HK (1) HK1208687A1 (fr)
IL (1) IL236617A0 (fr)
IN (1) IN2015KN00350A (fr)
MX (1) MX2015000565A (fr)
NI (1) NI201500002A (fr)
NZ (1) NZ704269A (fr)
PE (1) PE20150360A1 (fr)
PH (1) PH12015500084A1 (fr)
SG (1) SG11201500233PA (fr)
TW (2) TWI636061B (fr)
UA (1) UA117659C2 (fr)
WO (1) WO2014012007A2 (fr)
ZA (1) ZA201500872B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009003229A (es) 2006-09-29 2009-06-18 Oncomed Pharm Inc Composiciones y metodos para diagnosticar y tratar cancer.
SI2173379T1 (sl) 2007-07-02 2015-12-31 Oncomed Pharmaceuticals, Inc. Sestavki in postopki za zdravljenje in diagnosticiranje raka
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
EP2720721B1 (fr) 2011-06-17 2017-08-30 President and Fellows of Harvard College Frizzled 2 en tant que cible pour des anticorps thérapeutiques dans le traitement du cancer
US8802097B2 (en) 2011-07-15 2014-08-12 Oncomed Pharmaceuticals, Inc. Anti-RSPO1 antibodies
WO2014012007A2 (fr) 2012-07-13 2014-01-16 Oncomed Pharmaceuticals, Inc. Agents de liaison des protéines rspo3 et leurs utilisations
BR112016008477A2 (pt) * 2013-10-18 2017-10-03 Genentech Inc Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
JP2017526641A (ja) 2014-07-11 2017-09-14 ジェネンテック， インコーポレイテッド Ｎｏｔｃｈ経路阻害
CA2961374A1 (fr) 2014-09-16 2016-03-24 Oncomed Pharmaceuticals, Inc. Traitement de maladies fibrotiques
MA41123A (fr) * 2014-12-02 2017-10-10 Oncomed Pharm Inc Polythérapie pour le traitement du cancer
WO2017040660A1 (fr) * 2015-08-31 2017-03-09 Oncomed Pharmaceuticals, Inc. Polythérapie pour le traitement d'une maladie
CN106913880B (zh) * 2015-12-24 2021-02-12 上海交通大学 一种含有rspo1的靶向给药系统及其制备与应用
CN105925576B (zh) * 2016-03-24 2018-04-20 嘉兴市第一医院 针对哺乳动物R‑Spondin3基因靶点的小干扰RNA、短发卡RNA及载体和应用
EP3443004A1 (fr) 2016-04-14 2019-02-20 H. Hoffnabb-La Roche Ag Anticorps anti-rspo3 et méthodes d'utilisation de ceux-ci
WO2018035210A1 (fr) * 2016-08-17 2018-02-22 Oncomed Pharmaceuticals, Inc. Méthodes et surveillance d'un traitement basé sur un antagoniste de rspo
EP4115904A3 (fr) 2017-12-07 2023-04-12 National Health Research Institutes Anticorps anti-rspo3
CN110339364B (zh) * 2018-04-02 2021-02-12 上海邦耀生物科技有限公司 Lgr4/rspo阻断剂与抗免疫检查点抑制剂联合用于肿瘤的免疫治疗
CN110467663B (zh) * 2019-06-18 2022-05-10 华南农业大学 Rspo3基因在母猪卵巢颗粒细胞中的应用
KR102554222B1 (ko) * 2023-03-21 2023-07-11 순천향대학교 산학협력단 신규한 항-인간 알스폰딘3 항체 및 이의 용도
CN116769030B (zh) * 2023-08-21 2023-10-20 成都大熊猫繁育研究基地 一种大熊猫松弛素3单克隆抗体及其杂交瘤细胞株和应用

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US20070124581A1 (en) 1992-05-17 2007-05-31 Reena Khare Cell adhesion and extracellular matrix proteins
WO1998049302A1 (fr) 1997-04-25 1998-11-05 Genetics Institute, Inc. Proteines secretees et polynucleotides les codant
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
JP2001517441A (ja) 1997-09-24 2001-10-09 メルク エンド カムパニー インコーポレーテッド Ｇタンパク質共役糖タンパク質ホルモン受容体ｈｇ３８
US20020065394A1 (en) 1998-03-18 2002-05-30 Kenneth Jacobs Secreted proteins and polynucleotides encoding them
ES2332025T3 (es) 1998-03-26 2010-01-22 The Board Of Trustees Of The Leland Stanford Junior University Nuevos receptores de mamiferos acoplados a la proteina g que tienen regiones extracelulares de repeticion ricas en leucina.
US6485972B1 (en) 1998-10-15 2002-11-26 President And Fellows Of Harvard College WNT signalling in reproductive organs
US20030166047A1 (en) 1999-05-06 2003-09-04 Millennium Pharmaceuticals, Inc. Lgr6 nucleic acids and uses thereof
AU6117000A (en) 1999-07-26 2001-02-13 Genentech Inc. Novel polynucleotides and method of use thereof
AU2001234944A1 (en) 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
US6824973B2 (en) 2000-02-03 2004-11-30 Kirin Beer Kabushiki Kaisha Method of promoting stem cell proliferation or survival by contacting a cell with a stem cell factor-like polypeptide
WO2001074164A1 (fr) 2000-03-31 2001-10-11 The General Hospital Corporation Procede modulant la croissance du cheveu
CA2405104A1 (fr) 2000-04-05 2001-10-18 Kirin Beer Kabushiki Kaisha Methodes et materiaux relatifs a de nouveaux polypeptides et polynucleotides du type facteur de croissance des cellules-souches
EP1156062A1 (fr) 2000-05-12 2001-11-21 GPC Biotech AG Peptides/protéines immunomodulants et liants à un antigène du CMH classe II humain
AU2001263006A1 (en) 2000-05-18 2001-11-26 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001281791A1 (en) 2000-05-30 2001-12-11 Bayer Aktiengesellschaft Regulation of human lgr4-like g protein-coupled receptor
WO2003050502A2 (fr) 2001-12-07 2003-06-19 Regents Of The University Of Michigan Identification et caracterisation prospectives des cellules souches cancereuses du sein
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US6768004B2 (en) 2001-01-11 2004-07-27 Mueller Sybille Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1F7, an anti-idiotypic antibody reactive with anti-HIV antibodies
US20040077048A1 (en) 2002-01-30 2004-04-22 Warren Bridget A. Protein modification and maintenance molecules
US20100292155A1 (en) 2001-03-05 2010-11-18 Arca Biopharma, Inc. Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
US20030032034A1 (en) 2001-03-05 2003-02-13 Tang Y. Tom Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
US7411052B2 (en) 2001-03-05 2008-08-12 Nuvelo, Inc. Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
AU2002304249A1 (en) 2001-06-11 2002-12-23 Kirin Beer Kabushiki Kaisha Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and dna coding for the same
DE60233509D1 (de) 2001-06-20 2009-10-08 Fibron Ltd Fgfr3 blockierende antikörper, verfahren zum screening darauf und verwendungen davon
US20030022217A1 (en) 2001-07-02 2003-01-30 Pe Corporation (Ny) Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
EP2228443A1 (fr) 2001-08-30 2010-09-15 ARCA biopharma, Inc. Méthodes et matériaux concernant les polypetide similaire au Stem Cell Growth Factor et les polynucléotides les codant
CA2462795A1 (fr) 2001-10-03 2003-04-10 Incyte Genomics, Inc. Proteines secretees
US20070237770A1 (en) * 2001-11-30 2007-10-11 Albert Lai Novel compositions and methods in cancer
US20040197778A1 (en) 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
AU2002366951A1 (en) 2001-12-10 2003-07-09 Nuvelo,Inc. Novel nucleic acids and polypeptides
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
WO2003091280A1 (fr) 2002-04-26 2003-11-06 Kirin Beer Kabushiki Kaisha Polypeptide a activite entretenant la proliferation ou la survie de cellules souches hematopoietiques ou de progeniteurs hematopoietiques, et adn codant ce polypeptide
EP1380644A1 (fr) 2002-07-08 2004-01-14 Kylix B.V. Utilisation de gènes cible spécifiques de TCF pour identifier des medicaments pour le traitement du cancer, en particulier le cancer colorectal, dans lequel TCF/beta-catenin/WNT signalisation joue un rôle central
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
WO2004074436A2 (fr) 2003-02-19 2004-09-02 Incyte Corporation Procede d'utilisation d'un gpcr pour diagnostiquer et traiter le cancer du colon et du poumon
US20050003405A1 (en) 2003-04-30 2005-01-06 Hua-Chien Chen Treatment and diagnostics of cancer
EP2481814A3 (fr) 2003-06-09 2012-10-10 The Regents of the University of Michigan Compositions et procédés de diagnostic et de traitement des cancers
WO2005110009A2 (fr) 2003-07-22 2005-11-24 Immunex Corporation Compositions et methodes relatives aux tsp-30a, b, c et d
DE10339820A1 (de) 2003-08-22 2005-03-17 Hinzmann, Bernd, Dr. Verwendung von an GPR49 bindenden Substanzen zur Diagnose und Behandlung von Krebs
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
PL2157192T3 (pl) 2003-10-10 2014-01-31 Deutsches Krebsforsch Kompozycje do diagnozowania i terapii chorób związanych z nieprawidłową ekspresją futrin (R-spondin)
WO2005040828A2 (fr) 2003-10-24 2005-05-06 Bayer Healthcare Ag Agents de diagnostic et de traitement des maladies associees au recepteur 49 couple aux proteines g (gpr49)
SG149059A1 (en) 2004-01-27 2009-01-29 Nuvelo Inc Gastrointestinal proliferative factor and uses thereof
WO2005074633A2 (fr) 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions et procédés permettant de caractériser, de réguler, de diagnostiquer et de traiter des cancers
US20080187954A1 (en) 2004-03-10 2008-08-07 Lonza Ltd. Method For Producing Antibodies
MX2007002883A (es) 2004-09-13 2007-06-15 Macrogenics Inc Anticuerpos humanizados contra el virus de nilo occidental y usos terapeuticos y profilacticos del mismo.
AU2005318171B2 (en) 2004-12-20 2011-09-29 Crucell Holland B.V. Binding molecules capable of neutralizing West Nile virus and uses thereof
US7439327B2 (en) 2005-01-18 2008-10-21 Nuvelo, Inc. Stem cell factor-like proteins and uses thereof
WO2006110585A2 (fr) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. Genes lies au cancer (prlr)
US20090036369A1 (en) 2005-07-26 2009-02-05 Kirin Pharma Kabushiki Kaisha Anti-tumor agents comprising r-spondins
US7541431B2 (en) 2005-09-07 2009-06-02 Maine Medical Center Cristin/R-spondin ligands active in the Wnt signaling pathway and methods, compositions and kits relating thereto
WO2007100357A2 (fr) 2005-10-07 2007-09-07 Nuvelo, Inc. Scfa1, protéine du type facteur des cellules souches et utilisations de celle-ci
JP5129149B2 (ja) 2005-10-31 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
NO345476B1 (no) 2006-06-02 2021-02-22 Xoma Technology Ltd Bindingsproteiner for hepatocyttvekstfaktor (HGF)
MX2008015138A (es) 2006-06-02 2009-01-28 Aveo Pharmaceuticals Inc Proteinas de union al factor de crecimiento de hepatocitos (fch).
WO2007145840A2 (fr) 2006-06-13 2007-12-21 Oncomed Pharmaceuticals, Inc. Compositions et procédés de diagnostic et de traitement du cancer
ES2673822T3 (es) * 2006-07-18 2018-06-25 Sanofi Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer
JP2008044926A (ja) 2006-08-14 2008-02-28 Trustees Of Columbia Univ In The City Of New York Ｗｎｔ信号伝達に関係した分泌タンパク質
MX2009003229A (es) 2006-09-29 2009-06-18 Oncomed Pharm Inc Composiciones y metodos para diagnosticar y tratar cancer.
US8088374B2 (en) 2006-10-20 2012-01-03 Deutsches Krebsforschungszentrum Stiftung Des Offenlichen Rechts Methods for inhibition of angiogenesis and vasculogenesis via rspondin antagonists
WO2008075796A1 (fr) 2006-12-21 2008-06-26 Kyowa Hakko Kirin Co., Ltd. Agent pour encourager la récupération après une déplétion de globule sanguin
WO2008088524A2 (fr) 2006-12-28 2008-07-24 Nuvelo, Inc. Protéine r-spondine 1 à carence en domaines de thrombospondine utilisee en tant que facteur de prolifération épithéliale du tractus gastro-intestinal
BRPI0812562A2 (pt) 2007-06-12 2019-09-24 Trubion Pharmaceuticals Inc composições terapêuticas anti-cd20 e métodos
SI2173379T1 (sl) 2007-07-02 2015-12-31 Oncomed Pharmaceuticals, Inc. Sestavki in postopki za zdravljenje in diagnosticiranje raka
US20120082659A1 (en) 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
CA2700257A1 (fr) 2007-10-02 2009-04-09 Hartmut Land Methodes et compositions associees aux reponses synergiques aux mutations oncogenes
JP5676107B2 (ja) 2007-11-14 2015-02-25 中外製薬株式会社 抗ｇｐｒ４９抗体を用いる癌の診断および治療
EP2313435A4 (fr) 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc Protéines se liant au récepteur 3 du facteur de croissance des fibroblastes (fgfr3)
WO2010016766A2 (fr) 2008-08-08 2010-02-11 Koninklijke Nederlandse Akademie Van Wetenschappen Anticorps reconnaissant un lgr5 et/ou un lgr6 humain endogène
EP2363471B1 (fr) * 2008-10-31 2016-10-12 Toray Industries, Inc. Procédé d'immunoessai pour la protéine cxcl1 humaine
US20120039912A1 (en) 2009-04-15 2012-02-16 Galapagos Sasu Rspondin-3 inhibition in bone disorders
US20120165270A1 (en) 2009-04-27 2012-06-28 Yeon Sook Choi Inhibition of hair follicle growth by the wnt inhibitor dkk1
CN102459346B (zh) * 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
CN102695499A (zh) 2009-06-18 2012-09-26 惠氏有限责任公司 小模块免疫药物的冻干制剂
WO2011009090A1 (fr) 2009-07-16 2011-01-20 Xoma Technology Ltd. Anticorps dirigés contre l’antigène de poids moléculaire élevé associé au mélanome
WO2011028683A1 (fr) 2009-09-03 2011-03-10 Schering Corporation Anticorps anti-gitr
EP2977060A1 (fr) 2009-12-23 2016-01-27 Deutsches Krebsforschungszentrum Récepteurs de rspo2 et rspo3
WO2011085289A1 (fr) 2010-01-11 2011-07-14 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Production d'un anticorps monoclonal thérapeutique contre le virus west nile chez les plantes
JP6034696B2 (ja) 2010-02-12 2016-11-30 オンコメッド ファーマシューティカルズ インコーポレイテッド ポリペプチド発現細胞の同定及び単離の方法
EP2659005A4 (fr) * 2010-12-28 2016-08-24 Caris Mpi Inc Profilage moléculaire pour le cancer
GB201106395D0 (en) 2011-04-14 2011-06-01 Hubrecht Inst Compounds
PL2702412T3 (pl) * 2011-04-28 2018-01-31 Sbi Biotech Co Ltd Przeciwciało przeciwko ludzkiej białkowej fosfatazie tyrozynowej typu receptorowego
US8802097B2 (en) 2011-07-15 2014-08-12 Oncomed Pharmaceuticals, Inc. Anti-RSPO1 antibodies
US9296826B2 (en) 2011-10-14 2016-03-29 Novartis Ag Antibodies and methods for WNT pathway-related diseases
WO2013067055A1 (fr) 2011-11-01 2013-05-10 Bionomics, Inc. Procédés de blocage de la croissance des cellules souches cancéreuses
EP2773664A1 (fr) 2011-11-01 2014-09-10 Bionomics, Inc. Anticorps anti-gpr49
RU2014133069A (ru) 2012-02-11 2016-04-10 Дженентек, Инк. Транслокации r-спондина и способы с их использованием
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
WO2014012007A2 (fr) 2012-07-13 2014-01-16 Oncomed Pharmaceuticals, Inc. Agents de liaison des protéines rspo3 et leurs utilisations
AU2014248568B2 (en) 2013-03-12 2017-07-13 Curegenix, Inc. Compounds for treatment of cancer
WO2014192974A1 (fr) 2013-05-30 2014-12-04 株式会社オーダーメードメディカルリサーチ Réactif contenant des anticorps anti-lgr6 pour la détection et le diagnostic du cancer
BR112016008477A2 (pt) 2013-10-18 2017-10-03 Genentech Inc Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
US9777052B2 (en) 2014-12-02 2017-10-03 The Board Of Regents Of The University Of Oklahoma R-spondin variants, compositions, and methods of use
MA41123A (fr) 2014-12-02 2017-10-10 Oncomed Pharm Inc Polythérapie pour le traitement du cancer

Also Published As

Publication number Publication date
JP6335896B2 (ja) 2018-05-30
IL236617A0 (en) 2015-02-26
CL2015000097A1 (es) 2015-07-10
ZA201500872B (en) 2016-06-29
TW201416378A (zh) 2014-05-01
MX2015000565A (es) 2015-04-10
TWI636061B (zh) 2018-09-21
EA032038B1 (ru) 2019-03-29
AU2013289990A1 (en) 2015-02-19
IN2015KN00350A (fr) 2015-07-10
EA201590144A1 (ru) 2015-08-31
WO2014012007A4 (fr) 2014-05-30
TW201906861A (zh) 2019-02-16
WO2014012007A3 (fr) 2014-04-03
US20140017253A1 (en) 2014-01-16
US20170267776A1 (en) 2017-09-21
US9181333B2 (en) 2015-11-10
NZ704269A (en) 2016-05-27
CN104854132A (zh) 2015-08-19
US20160108130A1 (en) 2016-04-21
HK1208687A1 (en) 2016-03-11
ECSP15005280A (es) 2016-01-29
AU2013289990B2 (en) 2018-06-14
WO2014012007A2 (fr) 2014-01-16
US9598497B2 (en) 2017-03-21
PH12015500084A1 (en) 2015-03-02
EP2872175A4 (fr) 2016-04-20
BR112015000776A2 (pt) 2017-08-15
PE20150360A1 (es) 2015-03-20
EP2872175A2 (fr) 2015-05-20
NI201500002A (es) 2015-07-16
UA117659C2 (uk) 2018-09-10
KR20150036603A (ko) 2015-04-07
JP2015529641A (ja) 2015-10-08
CA2878868A1 (fr) 2014-01-16

Similar Documents

Publication Publication Date Title
HK1208687A1 (en) Rspo3 binding agents and uses thereof rspo3
HK1199023A1 (en) Substituted benzothienylpyrrolotriazines and uses thereof
HK1202545A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
HK1203493A1 (en) Substituted azabicycles and use thereof
HK1200822A1 (en) Substituted dipyridylamines and uses thereof
IL237309A0 (en) Benzocyclooctyne compounds and uses thereof
ZA201400525B (en) Rspo binding agents and uses thereof
HK1210949A1 (en) Combinations and uses thereof
GB201216649D0 (en) Agents and methods
HK1203198A1 (en) Substituted phenylimidazopyrazoles and use thereof
HK1210809A1 (en) Beta-hexosyl-transferases and uses thereof
IL237400A0 (en) Rhizobacteria and its uses
PL2830587T3 (pl) Kompozycja o balansującym i ochronnym wpływie na skórę
EP2922862A4 (fr) Agents de formation-modulation de complexes et leurs utilisations
GB201222541D0 (en) Kiddibidet and pottibidet
GB201222342D0 (en) Compounds and uses thereof
GB201215414D0 (en) Composition and use
IL218974A0 (en) Conaction bitwen coutch and playels
GB201202021D0 (en) Co-sleeper and breastfeeder
GB201214749D0 (en) Compounds and their uses